Brevan Howard Capital Management
EWTX icon

Brevan Howard Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Brevan Howard Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
+26,566
New +$916K 0.01% 1017
2025
Q3 		– Sell
-13,561
Closed -$178K – 2027
2025
Q2 		$178K Buy
+13,561
New +$196K ﹤0.01% 1731
2025
Q1 		– Sell
-25,346
Closed -$677K – 1252
2024
Q4 		$677K Buy
25,346
+14,095
+125% +$449K ﹤0.01% 532
2024
Q3 		$300K Buy
+11,251
New +$224K ﹤0.01% 860

Other funds holding EWTX

OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Paradigm Biocapital Advisors
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jupiter Topco
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Driehaus Capital Management
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Brevan Howard Capital Management's EWTX Position: Q2 2026 in Review

Brevan Howard Capital Management opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 26,566 shares worth $1.08M. The stake represents 0.01% of the portfolio and ranks #1017 among its holdings. This is a return to the name: Brevan Howard Capital Management previously reported a position in EWTX as recently as Q2 2025.

Brevan Howard Capital Management first reported a position in EWTX in Q3 2024 and has held it in 4 quarters since. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Brevan Howard Capital Management held 26,566 shares of Edgewise Therapeutics worth $1.08M as of Q2 2026.
  • Edgewise Therapeutics was a new Brevan Howard Capital Management position in Q2 2026.
  • Edgewise Therapeutics made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1017 holding.
  • Brevan Howard Capital Management first reported a position in Edgewise Therapeutics in Q3 2024 and has held it in 4 quarters since.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.